Welcome to Chemren.com!Help Center 中文 Sign upLogin
Post Information
Products Suppliers Technologies Group Buying Surplus
Organic Raw Materials
Hydrocarbon Compounds Alcohols、Phenols、Ethers Aldehydes、Ketones、Quinones Esters Carboxylic Acids Halides Aromatic Compounds Heterocyclic Compounds Amino Acids、Proteins、Nucleic Acids Nitrogenous Organic Compounds Nitrogenous Organic Compounds Phosphorated Organic Compounds Sulfurated Organic Compounds Other Elemental Organic Compounds Organic Salts Carbohydrates Others
Organic Intermediates
Synthetic Intermediates Other Intermediates
Biochemicals and Pharmaceutical Chemicals
APIs Pharmaceutical Intermediates Biological Products Pharmaceutical Excipients Veterinary Drugs Finished Dosage Forms Pharmaceutical Impurities
Pesticides Fertilizers Pesticide Intermediates Others
Food and Feed Additives
Food Additives Feed Additives
Flavors and Fragrances
Flavors and Essences Spices Flavor and Fragrance Intermediates
Dyes and Pigments
Dyes Pigments Dye Intermediates
Catalysts and Additives
Additives and Auxiliaries Catalysts
Coatings and Paints
Coatings Paints Inks Others
Organic Adhesives Inorganic Adhesives
Inorganic Chemicals
Inorganic Salts Inorganic Acids Inorganic Alkalines Inorganic Oxides Elements Halides Others
Natural Products and Extracts
Plant Extracts Herbal Extracts Natural Products
Material Chemicals
Polymer Materials Metal and Ceramic Materials Nanomaterials
Electronic Chemicals
OFET Materials Electrode Materials Liquid Crystals
Household Chemicals
Cosmetics Oral Care Chemicals Skin Care Chemicals Household Insecticides Detergent Chemicals
Heat Exchange Equipment Reaction Equipment Crushing Equipment Mixing Equipment Separation Equipment Pressure Vessel Refrigeration Equipment Mass Transfer Equipment Molding Equipment Storage/Transport Equipment Drying Equipment Green Facilities Pump/Valve Equipment Conveying Equipment Instrumentation Auxiliary Equipment Crystallization Equipment Seal Machinery Heating Equipment Other Chemical Equipment
Other Chemicals
Other Chemicals
Location:Home > News Detail

US court rules in favour of Amgen in Enbrel patent case

Last Update:2019-08-13   |   Comments:0 A+ A-

Brief:The US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine.

 US court rules in favour of Amgen in Enbrel patent case

The US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine.


Amgen companies Immunex and Amgen Manufacturing and also Roche, owner of the patents, filed the patent litigation against Novartis unit Sandoz’s Erelzi (etanercept-szzs) drug, a biosimilar to Enbrel.


Before the court trial, Sandoz agreed that its biosimilar infringes seven patent claims in the US, said Amgen. The trial was regarding Sandoz’s challenges of the validity of the patent claims.


According to the court’s ruling, Sandoz failed to prove the seven asserted claims as invalid. The company signed a preliminary injunction agreement with Immunex / Amgen concerning the etanercept biosimilar.


In response to the decision, Sandoz has announced plans to appeal to the US Court of Appeals for the Federal Circuit.


Sandoz US president and North America head Carol Lynch said: “Sandoz respectfully disagrees with the court’s ruling, which prevents us from launching an additional treatment option for patients with autoimmune and inflammatory diseases.


“We will appeal this decision and look forward to presenting our case to the Federal Circuit, bringing Erelzi to US patients as soon as possible.”


The US Food and Drug Administration (FDA) accepted Sandoz’s biologics licence application (BLA) for the biosimilar in October 2015 and later approved the drug in August 2016.


Etanercept is a tumour necrosis factor alpha (TNF-alpha) inhibitor meant for various autoimmune diseases, including rheumatoid arthritis and psoriasis.


Sandoz’s Erelzi has been evaluated in a global development programme, which included preclinical studies, pharmacokinetic studies and a Phase III confirmatory safety and efficacy trial called EGALITY.


Amgen and Novartis are also involved in litigation over migraine drug Aimovig.


In April, Novartis filed a lawsuit against Amgen for allegedly trying to back out of their agreements relating to Aimovig.


Amgen sued back, claiming that Novartis breached their deals by working on a competitor drug.


About Us
Contact Us
User Agreement
Privacy Policy
Resource Docking
Offline Activities
Technical Services
Sales Promotion
Update Info
Retrieve Password
Sign Up
User Center
Product Presales
Technology Purchase
Technology Transfer
Sell Products